PTGX - NOTRELOAD AI

SLN/ 08/10/2026 · 8:55 AM

Silence Therapeutics’ Divesiran Delivers Strong Phase 2 Results in Rare Blood Cancer, Setting Up Challenge to Takeda

Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.

ALMS/ 03/30/2026 · 12:56 PM

Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data

Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.

Featured/ PTGX/ 10/10/2025 · 12:03 PM

J&J Looks to Acquire Protagonist to Bolster Pipeline Amid Stelara Competition

Johnson & Johnson is reportedly discussing the purchase of Protagonist Therapeutics. This move could boost J&J's drug portfolio, especially in treatments for immune conditions and blood cancers.

#PTGX↓

Silence Therapeutics’ Divesiran Delivers Strong Phase 2 Results in Rare Blood Cancer, Setting Up Challenge to Takeda

Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data

J&J Looks to Acquire Protagonist to Bolster Pipeline Amid Stelara Competition